Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:14pm CET

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum™ MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum™ MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt

For full U.S. Prescribing Information for Fanapt, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 21:13:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
11/15 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
11/13 VANDA PHARMACEUTICALS : Announces Participation at November 2017 Investor Confer..
11/10 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
11/10 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
11/08 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
11/07 VANDA PHARMACEUTICALS : reports 3Q loss
11/07 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
11/07 VANDA PHARMACEUTICALS : Reports Third Quarter 2017 Financial Results
11/07 VANDA PHARMACEUTICALS INC. : to Host Earnings Call
11/02 VANDA PHARMACEUTICALS : to Announce Third Quarter 2017 Financial Results on Nove..
More news
News from SeekingAlpha
11/10 Vanda strikes out in appeal of thumbs down from European advisory group on Fa..
11/07 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q3 2017 Results - ..
11/07 Vanda Pharmaceuticals beats by $0.08, misses on revenue
11/06 Notable earnings after Tuesday?s close
10/31 BIOSCIENCE CATALYSTS : Global Blood Therapeutics And Vanda Pharmaceuticals
Financials ($)
Sales 2017 164 M
EBIT 2017 -22,3 M
Net income 2017 -16,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 3,57x
Capi. / Sales 2018 3,00x
Capitalization 586 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,0 $
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.-18.81%586
GILEAD SCIENCES1.16%94 196
REGENERON PHARMACEUTICALS6.67%41 388
VERTEX PHARMACEUTICALS100.10%36 580
GENMAB4.43%11 537
EXELIXIS, INC.76.93%7 589